[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemorrhoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemorrhoid":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,83,123,153,178,208,236,258,292,315,342,367],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100613271","bleeding-reduction-in-grade-ii-iii-haemorrhoids-through-embolization-treatment-100613271",false,"NCT07264413","Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment","BRIGHT","Inclusion Criteria:\n\n1. Adult patients presenting bleeding Grade II-III haemorrhoids with French bleeding score ≥3 planned to be treated with HAE using embolization coils;\n2. Patients competent and willing to give written informed consent.\n\nExclusion Criteria:\n\n1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);\n2. Patients receiving HAE using a combination of coils and particles, particles only, or any other embolic agents;\n3. Patients who have had previous surgical haemorrhoidectomy at any time or other treatments for haemorrhoids within 1 year before the planned HAE;\n4. Patients with known perianal sepsis, inflammatory bowel disease, peri-anal fistula, colorectal malignancy or pre-existing sphincter injury resulting in incontinence;\n5. Patients with an immunodeficiency;\n6. Known severe atheromatous disease with occlusion of target vessels preventing embolization;\n7. Absolute contraindication to contrast media;\n8. ECOG performance status \\> 2;\n9. Life expectancy \\\u003C 12 months;\n10. Patients with unstable angina;\n11. Patients currently taking nicorandil.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","BRIGHT is a Europe-wide study that will follow up to 250 adults with bleeding symptoms from haemmorhoids (Grade II-III categories). It aims to understand how well a minimally invasive procedure called haemorrhoid artery embolization (HAE) works in everyday clinical practice, which is a technique that blocks the blood vessels feeding the haemorrhoids. As this technique does not require major surgery, HAE offers several benefits such as less trauma, quicker recovery, and the use of only local anaesthesia.",[24,25],"Hemorrhoid","Hemorrhoid Bleeding",[27,28,29,30,31,32,33,34,35,36,37],"Haemorrhoids","Grade II-III haemorrhoids","Symptomatic haemorrhoids","Hemorrhoidal bleeding","Haemorrhoidal disease","Haemorrhoid artery embolization","HAE","Artery embolization","Transarterial embolization","Minimally invasive","Embolization coils","NOT_YET_RECRUITING","2026-07-01",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":20},"2026-08",{"date":46,"type":20},"2030-12",{"name":48,"class":49},"Cardiovascular and Interventional Radiological Society of Europe","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":80,"locationsCount":82},"100643992","phase-3-nimsai-herbal-for-grade-2-3-hemorrhoids-a-quadruple-blind-placebo-controlled-mechanistic-trial-100643992","NCT07669662","Nimsai Herbal for Grade 2-3 Hemorrhoids: A Quadruple-Blind Placebo-Controlled Mechanistic Trial","Quadruple-Blind, Placebo-Controlled, Parallel-Group Randomized Controlled Trial to Evaluate the Efficacy and Safety of Nimsai Herbal in Patients With Grade 2-3 Hemorrhoids","NAJ2","Inclusion Criteria:\n\n* Endoscopically confirmed Grade 2 or 3 internal hemorrhoids\n\nHistory of hemorrhoidal symptoms persisting for more than 6 weeks prior to screening\n\nAge 18 to 70 years inclusive at time of informed consent\n\nWillingness and ability to provide written informed consent\n\nWillingness and ability to comply with all study procedures, schedules, and follow-up requirements\n\nExclusion Criteria:\n\n* Diagnosis of Grade 1 or Grade 4 hemorrhoids\n\nAny known anorectal malignancy or suspicion of malignancy\n\nActive bleeding from sources other than hemorrhoids\n\nCurrently pregnant or lactating women, or women of childbearing potential not using effective contraception\n\nKnown hypersensitivity or allergy to any component of Nimsai Herbal or placebo\n\nSignificant systemic diseases including severe cardiovascular disease, severe renal impairment, severe hepatic dysfunction, or uncontrolled diabetes mellitus (HbA1c \\> 9%)\n\nAny medical or psychiatric condition that might compromise participant safety or data integrity\n\nParticipation in another interventional clinical trial within 30 days prior to screening\n\nUse of concurrent treatments for hemorrhoids within 7 days prior to screening\n\nHistory of hemorrhoidectomy or other invasive hemorrhoid procedures within the last 6 months","70 Years",{"count":60,"type":20},50,"INTERVENTIONAL",[63],"PHASE3","This randomized, quadruple-blind, placebo-controlled clinical trial evaluates the efficacy and safety of Nimsai Herbal, a proprietary oral phytotherapeutic formulation, in 50 participants aged 18-70 years with endoscopically confirmed Grade 2-3 internal hemorrhoids. Participants will be randomly assigned in a 1:1 ratio to receive either Nimsai Herbal (600 mg) or identical placebo once daily for 10 consecutive days. The primary endpoint is hemorrhoid regression at Day 10, defined as either a reduction in Goligher grade or a ≥75% reduction in composite hemorrhoid severity score. Secondary endpoints include change in symptom severity measured by Visual Analog Scale and complete symptom resolution rate. The study is designed as a mechanistic signal-detection investigation based on the War-Drill Model, which posits venous congestion as the primary initiating event in hemorrhoid pathogenesis.",[24,66],"Hemorrhoidal Disease",[68,69,70,71,72,73],"venous stasis","War-Drill Model","Parola Phenomenon","phytotherapy","Nimsai Herbal","quadruple-blind","2026-06-20",{"date":76,"type":42},"2026-06-25",{"date":78,"type":20},"2026-06-22",{"date":41,"type":20},{"name":81,"class":49},"Nimsai Academia",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":92,"conditions":93,"keywords":103,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100642579","case-specific-health-care-professional-clinical-survey-for-concerto-versa-detachable-coils-100642579","NCT07639853","Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils","Inclusion Criteria:\n\n1. Patient treated with Concerto Versa™ Detachable Coil is age ≥ 22 years at the time of procedure.\n2. Use of Concerto Versa™ Detachable Coil in accordance with the device labeling.\n3. Reporting of case within 72 hours of index procedure.","22 Years",{"count":91,"type":20},30,"The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.",[94,95,96,24,97,98,99,100,101,102],"Arteriovenous Malformation","Gastrointestinal Bleed","Gastric Varices","Pelvic Venous Disorders","Peripheral Aneurysms","Portal Vein Embolization","Type II Endoleak","Varicocele","Hemorrhage",[104,105,106,107,108,109,110,111,112],"Peripheral Vascular Disease","Vascular Disease","Arterial Embolization","Arteriovenous Embolization","Venous Embolization","Embolization Coils","Peripheral Embolization Coils","Peripheral Arterial Disease","Embolization","2026-06-11",{"date":115,"type":42},"2026-06-15",{"date":117,"type":20},"2026-07",{"date":119,"type":20},"2026-11",{"name":121,"class":122},"Medtronic Endovascular","INDUSTRY",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":21,"phases":4,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":82},"100643064","prospective-hemorrhoidal-embolisation-piles-registry-100643064","NCT07635784","Prospective HemorrhoIdaL EmboliSation (PILES) Registry","Creation Of a Prospective Registry For Hemorrhoid Artery Embolization At The Joint & Vascular Institute","PILES","Inclusion Criteria:\n\n* Adults (≥18 years) with symptomatic bleeding internal hemorrhoids refractory to medical therapy, referred for HAE.\n\nExclusion Criteria:\n\n* Pregnancy, coagulopathy, severe comorbidities, or inability to consent.",{"count":132,"type":20},1200,"5 Years","The goal of this observational study (prospective registry) is to collect long-term real-world data on the effectiveness and safety of hemorrhoid artery embolization (HAE) for symptomatic bleeding internal hemorrhoids in adults aged 18 years or older that have not responded to medical therapy.\n\nThe main question it aims to answer are:\n\n1\\) Does HAE lead to sustained improvement in bleeding (HDSS scores over 12-36 months?\n\nParticipants will:\n\n* Undergo HAE as part of their routine clinical care.\n* Complete clinical follow-up assessments at 1, 3, 6, 12, 18, 24, and 36 months after treatment, including symptom and quality-of-life questionnaires.\n* Have safety outcomes tracked according to Society of Interventional Radiology guidelines.\n\nThere is no comparison group; results will be analyzed to identify predictors of success and inform best practices for patient selection and treatment.",[24,136,25,137,138],"Internal Hemorrhoids","Hemorrhoidal Bleeding","Internal Hemorrhoid",[140,141,142],"bleeding","hemorrhoids","internal hemorrhoids","RECRUITING","2026-06-10",{"date":146,"type":42},"2026-06-12",{"date":148,"type":42},"2026-01-18",{"date":150,"type":20},"2032-01",{"name":152,"class":122},"Joint & Vascular Institute",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":61,"phases":162,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":82},"100638256","shape-versus-milligan-morgan-hemorrhoidectomy-for-hemorrhoidal-disease-100638256","NCT07598630","SHAPE Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal Disease","Early Outcomes of Skin-Sparing Hemorrhoidectomy and PExy (SHAPE) Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n* All patients with third- and fourth-degree piles, and their age greater than 18 years old\n\nExclusion Criteria:\n\n* Patients with inflammatory bowel disease.\n* Patients with anal stenosis\n* Patients with colorectal malignancy\n* Patient with fecal incontinence",{"count":161,"type":20},68,[163],"NA","This study will be conducted at the General Surgery Department, Kasr Al-Ainy Teaching Hospital, Cairo University, on patients presenting with third- and fourth-degree hemorrhoids. Adult patients older than 18 years who fulfill the inclusion criteria and provide informed consent will be enrolled. Patients with inflammatory bowel disease, anal stenosis, colorectal malignancy, or fecal incontinence will be excluded.\n\nAll patients will undergo detailed preoperative assessment including medical and surgical history, evaluation of anal symptoms, local anorectal examination, digital rectal examination, and routine laboratory investigations.\n\nParticipants will be randomized into two groups: Group A will undergo Skin-Sparing Hemorrhoidectomy and PExy (SHAPE), while Group B will undergo conventional Milligan-Morgan hemorrhoidectomy.\n\nPostoperatively, oral fluids will be allowed after 2 hours and normal diet resumed as tolerated. Patients will be discharged on the first postoperative day unless otherwise indicated. Follow-up visits will assess postoperative pain, complications, and surgical outcome",[24],[66,167,168],"SHAPE","Milligan-Morgan Hemorrhoidectomy","2026-05-16",{"date":171,"type":42},"2026-05-20",{"date":173,"type":20},"2026-05-24",{"date":175,"type":20},"2027-01-01",{"name":177,"class":49},"Cairo University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":186,"enrollmentInfo":187,"targetDuration":189,"studyType":21,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":82},"100615690","topical-nifedipine-03-plus-lidocaine-15-for-uncomplicated-hemorrhoidal-disease-100615690","NCT07295886","Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease","Observational Study on the Use of Topical Nifedipine 0.3% and Lidocaine 1.5% in Acute Uncomplicated Hemorrhoidal Disease","NILOS","Inclusion Criteria:\n\n* Male and female patients aged 18-75 years.\n* Clinical or anoscopic diagnosis of acute hemorrhoidal disease with prolapse severity between Grade II and IV (Goligher), possibly associated with external congestion.\n* Patients who started treatment with nifedipine 0.3% + lidocaine 1.5% within the past 5 days.\n* Availability of clinical evaluations at treatment initiation (proctologic visit and HDSS, SHS-HD, VAS scales).\n* Ability to understand the informed consent.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Acute hemorrhoidal disease complicated by thrombosis or strangulation.\n* Coagulopathies.\n* Active neoplastic disease.\n* Treatment with anticoagulants and\u002For chemotherapeutic agents.\n* Hypersensitivity to active substances, especially lidocaine (and other amide-type local anesthetics) or excipients.\n* Severe hypotensive states or cardiovascular insufficiency.\n* Pregnancy or breastfeeding.\n* Participation in clinical trials involving investigational drugs.","75 Years",{"count":188,"type":20},80,"30 Days","The goal of this observational study is to evaluate the effectiveness of topical nifedipine 0.3% plus lidocaine 1.5% for uncomplicated hemorrhoidal disease. The main question it aims to answer is:\n\nDoes topical nifedipine 0.3% plus lidocaine 1.5% lower symptoms in patients with uncomplicated acute hemorrhoidal disease? Participants already taking nifedipine 0.3% plus lidocaine 1.5% as part of their regular medical care for hemorrhoidal disease will undergo four visits over a 30-day period, including two telephone contacts and two in-person visits.",[25,192,193,24,194],"Hemorrhoids Prolapse","Hemorrhoid Pain","Topical Administration",[196,197,198],"nifedipine 0.3% plus lidocaine 1.5%","uncomplicated hemorrhoidal disease","hemorrhoids symptoms","2025-12-19",{"date":201,"type":42},"2025-12-22",{"date":203,"type":42},"2025-09-02",{"date":205,"type":20},"2026-05-02",{"name":207,"class":49},"Cardarelli Hospital",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":61,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":82},"100605193","lignocaine-vs-gtn-ointment-for-postoperative-pain-after-hemorrhoidectomy-100605193","NCT07159334","\"Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy\")","Role of Topical Application of Lignocaine Versus 0.2% Glyceryl Trinitrate (GTN) Ointment as a Postoperative Local Analgesic in Hemorrhoidectomy in Terms of Pain Score,Wound Healing Time and Patient Satisfaction Level","Inclusion Criteria:\n\n* Age between 18 - 60 years\n* Both genders\n* Grade III and IV hemorrhoids diagnosed on the basis of history and clinical examination by consultant Surgeon.(Grade III Hemorrhoid manually reduced by patient with finger and Grade IV is prolapsed)\n* ASA (American society of Anesthesia) grades I, and II\n\nExclusion Criteria:\n\n* Previously reported allergy or reaction to lignocaine and GTN\n* Pregnancy or lactation\n* Concomitant perianal pathology warranting surgery\n* Cardiovascular disease\n* Patient taking Nitrates or Calcium channel blocker","60 Years",{"count":217,"type":20},64,[163],"This study is being conducted at the Department of General Surgery, King Edward Medical University, Lahore, Pakistan. The purpose of the trial is to compare the effectiveness of topical Lignocaine ointment versus topical Glyceryl Trinitrate (GTN) ointment in reducing postoperative pain following hemorrhoidectomy.\n\nPatients undergoing hemorrhoidectomy will be randomly assigned to receive either Lignocaine ointment or GTN ointment applied locally after surgery. Pain relief will be assessed using a visual analog scale (VAS) at regular intervals during the postoperative period. The study aims to determine which ointment provides better pain control and improves patient comfort during recovery.",[24,221],"Postoperative Pain",[223,224,225,226],"Hemorrhoidectomy","Lignocaine ointment","Glyceryl Trinitrate ointment","Anal pain","2025-09-03",{"date":229,"type":42},"2025-09-08",{"date":231,"type":42},"2025-08-02",{"date":233,"type":20},"2025-12",{"name":235,"class":49},"King Edward Medical University",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":61,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":82},"100602858","phase-4-efficacy-and-safety-evaluation-of-ruscus-aculeatus-l-in-patients-with-hemorrhoids-100602858","NCT07128979","Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids","Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids: A Randomized, Double-blind Phase IV Clinical Trial","Inclusion Criteria:\n\n1. Patients between the ages of 18-45 with complaints (symptomatic) consistent with hemorrhoidal disease\n2. Patients with Stage II and III hemorrhoids according to the Goligher Hemorrhoid Rating system using physical examination (digital rectal examination, anoscopy\u002Frectoscopy performed within a maximum of four weeks before the examination)\n3. Patients who have signed the Informed Consent Form\n\nExclusion Criteria:\n\n* Patients aged \\\u003C18 and \\>45 years\n* Stage I and IV hemorrhoids according to the Goligher Hemorrhoid Rating system\n* Surgery for hemorrhoids at any time\n* Injection treatment for multiple hemorrhoids in the last 3 years\n* Perianal sepsis, inflammatory bowel disease, colorectal malignancy, or pre-existing sphincter injury within the last 3 years\n* Immunodeficiency\n* In addition to hemorrhoids, patients with anal fissures and perianal fistulas detected by simultaneous physical examination or anoscopy\u002Frectoscopy","45 Years",{"count":19,"type":20},[246],"PHASE4","Hemorrhoidal disease is characterized by distal displacement and deterioration of structural integrity of vascular cushions in the anal canal, which physiologically help defecation and continence. Unlike advanced stage (stage IV) hemorrhoids, which require surgical intervention, various topical agents (gels, ointments, creams), oral venoactive drugs, homeopathic and phytotherapeutic products and nutritional supplements are widely used in stage II and III hemorrhoidal disease. The genus Ruscus (family Asparagaceae) is a group of plants native to the Mediterranean basin, Southern and Western Europe, and Iran, represented by perennial, rhizome-based, and evergreen shrubs. Among the species belonging to this genus, Ruscus aculeatus L. has the widest distribution area. The subsoil parts of the Ruscus plant are rich in steroidal saponins and show vasoconstrictor, diuretic, anti-inflammatory and venotonic effects, especially with ruscogenin and neoruscogenin compounds. Due to these properties, R. aculeatus stands out as a traditional phytotherapy agent that has been used for a long time in chronic venous insufficiency. However, there are no controlled clinical studies in the literature evaluating the efficacy and safety of Ruscus aculeatus L. in hemorrhoidal disease. Therefore, this study was aimed to systematically evaluate the contribution of a phytotherapeutic product containing R. aculeatus to the treatment of stage II-III hemorrhoidal patients and to provide scientific evidence of a new and potentially safe herbal treatment option that can be used in the treatment of hemorrhoids.",[24],"2025-08-18",{"date":251,"type":42},"2025-08-19",{"date":253,"type":42},"2025-08-01",{"date":255,"type":20},"2026-11-02",{"name":257,"class":49},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":61,"phases":267,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100577427","effect-of-listening-to-standardized-music-sequences-on-preventing-postoperative-pain-in-proctologic-surgery-100577427","NCT06798155","Effect of Listening to Standardized Music Sequences on Preventing Postoperative Pain in Proctologic Surgery","MUSICOPROCTO","Inclusion Criteria:\n\n* Male or female, aged over 18 years.\n* Patient who has signed an informed consent form.\n* Patient scheduled to undergo proctological surgery (for hemorrhoids, fistula, or anal fissure) at the participating institution.\n* Must be affiliated with a social security system or be a beneficiary of such a system.\n* Patient must have access to the necessary technical means (smartphone, computer, tablet) to use the Music Care® application.\n\nExclusion Criteria:\n\n* Refusal to consent.\n* Patient unable to read, write, or understand French.\n* Vulnerable patient according to Article L1121-6 of the French Public Health Code (CSP).\n* Adult patient under guardianship or curatorship or under legal protection (safeguard of justice).\n* Patient unable to personally give informed consent according to Article L.1121-8 of the CSP or an adult protected by law.\n* Pregnant or breastfeeding women according to Article L1121-5 of the CSP.\n* Patient who has already participated in a study within the last 12 months.",{"count":266,"type":20},550,[163],"The study, \"Effect of Listening to Standardized Music Sequences on Preventing Postoperative Pain in Proctologic Surgery,\" aims to evaluate the impact of preoperative listening to standardized music sequences on postoperative pain in patients undergoing proctologic surgery (for hemorrhoids, fistulas, or anal fissures).\n\nThis research will assess the influence of preoperative music on postoperative pain management, the use of analgesics after surgery and during the following month, and its effect on the quality of life post-surgery.\n\nMUSICO-PROCTO is an interventional, randomized study involving two groups (patients will be randomly assigned to either the music intervention or control group). The study is monocentric, conducted at Clinique Saint Vincent in France, and includes 550 participants.\n\nParticipants will be followed for 28 days, while the overall study duration will span 28 months.\n\nTo participate, individuals must:\n\nBe aged 18 or older. Be affiliated with a social security system. Provide signed informed consent. Undergo proctologic surgery for hemorrhoids, fistulas, or anal fissures. This study seeks to explore the potential of music as a complementary method to improve postoperative outcomes.",[24,270,271,272],"Anal Fistulas","MUSICAL THERAPY","Anal Fissure and Fistula",[274,275,276,277,278,279,280,281],"Standardized Music Therapy","Proctologic Surgery","Pain Management","Analgesic Use","Randomized Controlled Trial","Music Intervention","Preoperative Care","Monocentric Study","2025-06-25",{"date":284,"type":42},"2025-06-26",{"date":286,"type":42},"2025-02-03",{"date":288,"type":20},"2027-07",{"name":290,"class":49},"Clinique Saint-Vincent",2,{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":300,"enrollmentInfo":301,"targetDuration":302,"studyType":21,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":82},"100594981","oral-aminaphtone-and-combined-lidocaine-100594981","NCT07026513","ORal Aminaphtone and Combined LidocainE","Observational Study on the Effectiveness of a First-line Therapy With Aminaphtone and Lidocaine Cream in Patients With Hemorrhoidal Disease: a Prospective Monocentric Cohort Study","ORACLE","Inclusion Criteria:\n\n* Adults aged 18 to 85 years\n* Diagnosis of symptomatic internal hemorrhoidal disease (Grade I-IV, Goligher classification)\n* First outpatient consultation for current symptoms\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Active proctologic conditions (e.g., anal fissures, fistulas, condylomas, neoplasms)\n* Inflammatory bowel disease (IBD)\n* Known HIV infection\n* Previous surgical treatment for hemorrhoidal disease (except outpatient procedures performed \\>6 months prior)\n* Current use of psychotropic, antibiotic, antifungal, immunomodulatory, or corticosteroid drugs\n* Known hypersensitivity to Capillarema® or Octosedan® components","85 Years",{"count":60,"type":20},"1 Month","This observational study, called ORACLE (ORal Aminaphtone and Combined LidocainE), is being conducted at Treviso Regional Hospital (Italy) to evaluate the effectiveness of a first-line treatment for patients with internal hemorrhoidal disease (HD). The study focuses on a combination therapy using an oral drug, aminaphtone (Capillarema®), and a topical cream with lidocaine (Octosedan®), compared to standard conservative care.\n\nHemorrhoidal disease is a common condition that can cause bleeding, discomfort, itching, and swelling in the anal area. Many patients experience symptoms that affect their quality of life, even when using standard treatments like fiber supplements and emollient creams.\n\nThis study involves two groups of patients:\n\n* One group will receive oral aminaphtone (Capillarema®) plus lidocaine cream (Octosedan®).\n* The other group will receive standard advice on diet and hydration, along with optional use of lidocaine cream and emollients.\n\nPatients will be followed for 30 days. The main goal is to measure how much the combination treatment improves hemorrhoidal symptoms compared to the standard treatment. This will be assessed using a score called HDSS (Hemorrhoidal Disease Symptom Score). The study will also evaluate quality of life using a specific questionnaire (SHS-HD) and assess how well patients tolerate the treatment.\n\nAbout 50 adult patients will take part, divided into two consecutive groups of 25 each. The study does not involve random assignment or blinding. All participants will be informed about the study procedures and give written consent.\n\nThe results of this study may help doctors better understand the role of aminaphtone in managing hemorrhoidal disease and could improve future treatment recommendations.",[24],"2025-06-10",{"date":307,"type":42},"2025-06-18",{"date":309,"type":42},"2025-05-08",{"date":311,"type":20},"2025-07-31",{"name":313,"class":314},"Treviso Regional Hospital","NETWORK",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":324,"studyType":21,"phases":4,"briefSummary":325,"conditions":326,"keywords":332,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":82},"100583583","cough-and-hemorrhoids-100583583","NCT06878209","Cough and Hemorrhoids","Is Cough a Predisposing Factor for Hemorrhoids? A Prospective, Analytical Study","Inclusion Criteria:\n\n1. Being 18 years of age or older\n2. Speaking and understanding Turkish\n3. To be mentally and cognitively capable of understanding the questions asked\n4. To agree to participate in the research\n5. individuals diagnosed with hemorrhoidal disease\n\nExclusion Criteria:\n\n1. Those with existing proctologic disease other than hemorrhoidal disease and pelvic floor disease\n2. Patients with previous surgery for hemorrhoidal disease\n3. Patients with hemorrhoidal disease caused by portal hypertension\n4. Patients during pregnancy and diagnosed with postpartum hemorrhoidal disease\n5. those with benign prostatic hyperplasia or neurogenic bladder that may cause increased intra-abdominal pressure",{"count":323,"type":20},134,"1 Day","The aim of the study is to investigate the relationship between hemorrhoids and cough by assessing the symptoms, duration, and severity of cough in patients who will present to the general surgery outpatient clinic of Muğla Education and Research Hospital (MERH) with symptoms such as bleeding, pain, itching, fecal leakage, prolapse, and mucus discharge. These patients will be diagnosed with hemorrhoidal disease through rectal examination to detect anal pathology and will be graded according to mucosal prolapse. Our study will aim to determine whether cough is a predisposing factor for hemorrhoids by evaluating the presence, duration, and frequency of cough symptoms in patients with hemorrhoids. The study will be designed as a cross-sectional, analytical, and descriptive study. Between March 2025 and June 2025, patients with newly diagnosed hemorrhoids who will present to the MEAH General Surgery Outpatient Clinic will undergo physical examinations and will be assessed for cough symptoms. Evaluations will include height and weight measurements, the Leicester Cough Questionnaire, the Cough Visual Analog Scale (VAS) questionnaire, duration of cough (categorized as acute if shorter than 4 weeks, or chronic if longer than 4 weeks), timing of cough (day, night, or all day), comorbidities (such as COPD, asthma, chronic bronchitis, interstitial lung disease, idiopathic pulmonary fibrosis, and others), and smoking history (active, former, or never smoked). The primary endpoint will be to compare the relationship between the severity of hemorrhoids and the duration and frequency of cough in patients with both conditions. The secondary endpoint will be to compare the grade of hemorrhoids with comorbid chest diseases in these patients. The tertiary endpoint will be to compare the degree of hemorrhoids with the smoking history of patients who have both hemorrhoids and cough.",[24,327,328,329,330,331],"Cough","Cough Duration","Cough Frequency","Cough Severity","Hemorrhoids, Internal",[333],"cough, hemorrhoid",{"date":335,"type":42},"2025-05-11",{"date":337,"type":42},"2025-03-14",{"date":339,"type":20},"2025-10-14",{"name":341,"class":49},"Muğla Sıtkı Koçman University",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":61,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":82},"100564128","trial-of-latex-vs-non-latex-hemorrhoid-banding-100564128","NCT06625138","Trial of Latex Vs Non-latex Hemorrhoid Banding","Single-blinded Randomized Trial of Latex Vs Non-latex Hemorrhoid Banding","NO-Tex","Inclusion Criteria:\n\n* Symptomatic grade 2-3 internal hemorrhoids undergoing rubber band ligation\n\nExclusion Criteria:\n\n* Previous hemorrhoidal banding within the past year\n* Known latex allergy\n* Pregnancy\n* Anticoagulation use\n* Bleeding disorder\n* Portal hypertension\n* Inflammatory bowel disease\n* Immunosuppression\n* Functional neurologic disorder\n* Pelvic floor dysfunction\n* Any records flagged \"break the glass\" or \"research opt out\".",{"count":351,"type":20},164,[163],"This study will involve the recruitment of adult patients with hemorrhoids for whom rubber band ligation is the recommended treatment. Patients will be randomized to receive banding with a latex band or non-latex band. Our goal will be to measure the performance of latex bands vs non-latex bands.",[24,25],[356,357],"hemorrhoid","banding","2024-10-24",{"date":360,"type":42},"2024-10-28",{"date":362,"type":42},"2024-08-30",{"date":364,"type":20},"2026-10-01",{"name":366,"class":49},"Huntington Memorial Hospital",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":374,"targetDuration":375,"studyType":21,"phases":4,"briefSummary":376,"conditions":377,"keywords":382,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":4},"100565179","hemorrhoidal-disease-in-inflammatory-bowel-disease-a-multicenter-prospective-cohort-study-100565179","NCT06638814","HEmorrhoidAl Disease in Inflammatory Bowel Disease: a Multicenter Prospective Cohort Study","HEAD-IBD-II","Inclusion Criteria:\n\n* age of 18 years and above;\n* established diagnosis of Crohn's disease or ulcerative colitis at the time of surgery for hemorrhoidal disease;\n* planned surgery for hemorrhoidal disease during the study period, including hemorrhoidectomy (open, close or submucosal), transanal hemorrhoidal dearterialization, hemorrhoidal laser procedure, stapled hemorrhoidopexy).\n\nExclusion Criteria:\n\n* previous surgery for hemorrhoidal disease other than office-based treatments (e.g., sclerotherapy injection, rubber band ligation);\n* active perianal disease at the time of surgical intervention.",{"count":60,"type":20},"12 Months","Patients who will undergo surgery for HD after the diagnosis of IBD over a 12-month period will be enrolled across Europe.\n\nPrimary objective of this study is to determine the safety and effectiveness of surgical treatments for HD in a large multicenter cohort of IBD patients.\n\nSecondary aim is to identify factors that may affect clinical and surgical outcomes.",[378,24,379,380,381],"IBD (Inflammatory Bowel Disease)","Safety","Sugery","Surgery Related Complications Rate",[372,383,384,385],"Hemorrhoidal disease","IBD","Surgery","2024-10-10",{"date":388,"type":42},"2024-10-15",{"date":390,"type":20},"2025-01-01",{"date":392,"type":20},"2027-01-31",{"name":313,"class":314}]